Study of BMS-477118 as Monotherapy With Titration in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise
2015年4月8日 更新者:AstraZeneca
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Saxagliptin as Monotherapy With Titration in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control With Diet and Exercise
The purpose of this trial is to understand if saxagliptin is more effective than placebo as a treatment for type 2 diabetic subjects who are not controlled with diet and exercise
研究概览
地位
完全的
条件
详细说明
All subjects will participate in a lead-in period, and qualifying subjects will continue into a short-term randomized treatment period.
Subjects who complete the short-term period will be eligible to enter the long term extension period.
Also, subjects in the short-term period who have an elevated blood sugar that requires additional medication for blood sugar control will be eligible to enter the long-term treatment extension period where they will receive metformin (rescue medication) added onto their blinded study medication
研究类型
介入性
注册 (实际的)
365
阶段
- 第三阶段
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习地点
-
-
-
Moscov、俄罗斯联邦、118089
- Local Institution
-
Moscow、俄罗斯联邦、115487
- Local Institution
-
Nizhniy Novgorod、俄罗斯联邦、603126
- Local Institution
-
Saint Petersburg、俄罗斯联邦、198013
- Local Institution
-
Saratov、俄罗斯联邦、410018
- Local Institution
-
Saratov、俄罗斯联邦、410054
- Local Institution
-
Smolensk、俄罗斯联邦、214018
- Local Institution
-
St.Petersburg、俄罗斯联邦、194156
- Local Institution
-
Volgograd、俄罗斯联邦、400138
- Local Institution
-
-
-
-
-
Bangalore、印度、560034
- Local Institution
-
Mumbai、印度、400007
- Local Institution
-
Mumbai、印度、400021
- Local Institution
-
Nagpur、印度、440012
- Local Institution
-
-
Karnataka
-
Manipal、Karnataka、印度、576104
- Local Institution
-
-
Kerala
-
Kochi、Kerala、印度、682026
- Local Institution
-
-
Mangalore
-
Attavar、Mangalore、印度、575001
- Local Institution
-
-
New Delhi
-
Sarita Vihar、New Delhi、印度、110076
- Local Institution
-
-
-
-
-
Changhua、台湾、500
- Local Institution
-
Kaohsiung County、台湾、833
- Local Institution
-
Taichung、台湾、402
- Local Institution
-
Taichung City、台湾、407
- Local Institution
-
Taipei City、台湾、114
- Local Institution
-
Tao-Yuan County、台湾、333
- Local Institution
-
-
-
-
Alabama
-
Columbiana、Alabama、美国、35051
- Tomac, Inc.
-
Haleyville、Alabama、美国、35565
- Winston Technology, Inc.
-
-
Arizona
-
Mesa、Arizona、美国、85213
- Clinical Reseacrh Advantage/ Brown Family Medicine
-
-
California
-
Bakersfield、California、美国、93311
- Strategos Medical Group
-
Burbank、California、美国、91505
- Providence Clinical Research
-
Cudahy、California、美国、90201
- Rx for Life, Inc
-
Encino、California、美国、91436
- Medical Group of Encino
-
Fountain Valley、California、美国、92708
- Southland Clinical Research Center, Inc.
-
Fresno、California、美国、93720
- Valley Research
-
Northridge、California、美国、91325
- Diabetes Medical Center Of California
-
Pico Rivera、California、美国、90660
- In Private Prictice Clinic
-
San Jose、California、美国、95128
- San Jose Clinical Research, Inc.
-
-
Florida
-
Altamonte Springs、Florida、美国、32714
- Central Florida Clinical Trials, Inc.
-
Melbourne、Florida、美国、32935
- Accelovance
-
Sarasota、Florida、美国、34243
- University Family Healthcare, Pa
-
St. Petersburg、Florida、美国、33707
- Premier Healthcare
-
-
Kansas
-
Overland Park、Kansas、美国、66215
- Pinnacle Medical Research
-
-
Missouri
-
Kansas City、Missouri、美国、64106
- Kansas City University Of Medicine And Biosciences
-
Wentzville、Missouri、美国、63385
- Primary Care Physicians, Pc
-
-
New Jersey
-
Toms River、New Jersey、美国、08755
- Physicians Research Center
-
-
New York
-
Kingston、New York、美国、12401
- Hudson Valley Clinical Research Center
-
-
North Carolina
-
Charlotte、North Carolina、美国、28262
- Neem Research Group of Charlotte
-
Greenville、North Carolina、美国、27834
- Diabetes Center- East Carolina University
-
Salisbury、North Carolina、美国、28144
- Crescent Medical Research
-
-
Ohio
-
Barberton、Ohio、美国、44203
- Community Health Care, Inc.
-
Canton、Ohio、美国、44718
- Clinical Research Limited
-
Kettering、Ohio、美国、45429
- Wells Institute for Health Awareness
-
Perrysburg、Ohio、美国、43551
- Clinical Research Source, Inc
-
-
Oklahoma
-
Oklahoma City、Oklahoma、美国、73112
- Accelovance
-
Oklahoma City、Oklahoma、美国、73170
- Integris Family Care South
-
-
Oregon
-
Eugene、Oregon、美国、97404
- The Office Of Patricia Buchanan
-
-
Pennsylvania
-
Carlisle、Pennsylvania、美国、17015
- Cumberland Valley Endocrinology Center, Llc
-
Fleetwood、Pennsylvania、美国、19522
- Fleetwood Clinical Research
-
Pittsburgh、Pennsylvania、美国、15216
- Banksville Medical, Pc
-
Shippensburg、Pennsylvania、美国、17257
- Biomedical Research Associates, Llc
-
-
South Carolina
-
Duncan、South Carolina、美国、29334
- Middle Tyger Family Medicine
-
Taylors、South Carolina、美国、29687
- Southeastern Research Assoc
-
-
Tennessee
-
Bartlett、Tennessee、美国、38134
- Versoza & Ungab Internal Medicine Associates
-
Collierville、Tennessee、美国、38017
- Collierville Medical Specialist
-
Kingsport、Tennessee、美国、37660
- Holston Medical Group
-
Memphis、Tennessee、美国、38116
- Med-South Research
-
Memphis、Tennessee、美国、38125
- Southwind Medical Specialist
-
-
Texas
-
Carrollton、Texas、美国、75010
- Precision Family Medicine
-
Corpus Christi、Texas、美国、78411
- Alpha Therapy Research Center
-
Houston、Texas、美国、77081
- Texas Center For Drug Development, P.A.
-
Houston、Texas、美国、77024
- Village Family Practice
-
San Antonio、Texas、美国、78224
- Abbott Clinical Research Group, Inc
-
-
Utah
-
Bountiful、Utah、美国、84010
- Taylor/Wade Medical
-
Salt Lake City、Utah、美国、84102
- Optimum Clinical Research
-
-
Virginia
-
Virginia Beach、Virginia、美国、23451
- Tidewater Integrated Medical Research
-
-
Washington
-
Spokane、Washington、美国、99216
- Spokane Internal Medicine
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
18年 至 77年 (成人、年长者)
接受健康志愿者
不
有资格学习的性别
全部
描述
Inclusion Criteria:
- Type 2 diabetes
- Inadequate blood sugar control
Exclusion Criteria:
- Previous treatment for diabetes
- Current treatment with other medications to lower blood sugar
- Major heart, liver or kidney problems
- Women who are pregnant or breastfeeding
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:双倍的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Saxagliptin 2.5 mg QAM (A)
PLUS open-label metformin (as needed as rescue medication)
|
Coated tablets, Oral, 2.5 mg, QAM, Daily (6 months ST, 12 months LT)
其他名称:
Coated tablets, Oral, 2.5 mg titrated to 5mg, QAM, Daily (6 months ST, 12 months LT)
其他名称:
Coated tablets, Oral, 5mg, QAM, Daily, (6 months ST, 12 months LT)
其他名称:
Coated tablets, Oral, 5mg QPM, Daily (6 months ST, 12 months LT)
其他名称:
Tablets, Oral, 500-2000 mg, as needed (12 months LT)
|
|
实验性的:Saxagliptin 2.5 mg titrated to 5 mg QAM (B)
PLUS open-label metformin (as needed as rescue medication)
|
Coated tablets, Oral, 2.5 mg, QAM, Daily (6 months ST, 12 months LT)
其他名称:
Coated tablets, Oral, 2.5 mg titrated to 5mg, QAM, Daily (6 months ST, 12 months LT)
其他名称:
Coated tablets, Oral, 5mg, QAM, Daily, (6 months ST, 12 months LT)
其他名称:
Coated tablets, Oral, 5mg QPM, Daily (6 months ST, 12 months LT)
其他名称:
Tablets, Oral, 500-2000 mg, as needed (12 months LT)
|
|
实验性的:Saxagliptin 5 mg QAM (C)
PLUS open-label metformin (as needed as rescue medication)
|
Coated tablets, Oral, 2.5 mg, QAM, Daily (6 months ST, 12 months LT)
其他名称:
Coated tablets, Oral, 2.5 mg titrated to 5mg, QAM, Daily (6 months ST, 12 months LT)
其他名称:
Coated tablets, Oral, 5mg, QAM, Daily, (6 months ST, 12 months LT)
其他名称:
Coated tablets, Oral, 5mg QPM, Daily (6 months ST, 12 months LT)
其他名称:
Tablets, Oral, 500-2000 mg, as needed (12 months LT)
|
|
实验性的:Saxagliptin 5 mg QPM (D)
PLUS open-label metformin (as needed as rescue medication)
|
Coated tablets, Oral, 2.5 mg, QAM, Daily (6 months ST, 12 months LT)
其他名称:
Coated tablets, Oral, 2.5 mg titrated to 5mg, QAM, Daily (6 months ST, 12 months LT)
其他名称:
Coated tablets, Oral, 5mg, QAM, Daily, (6 months ST, 12 months LT)
其他名称:
Coated tablets, Oral, 5mg QPM, Daily (6 months ST, 12 months LT)
其他名称:
Tablets, Oral, 500-2000 mg, as needed (12 months LT)
|
|
安慰剂比较:Placebo (E)
PLUS open-label metformin (as needed as rescue medication)
|
Tablets, Oral, 500-2000 mg, as needed (12 months LT)
Coated tablets, Oral, 0mg, Daily (6 months ST, 12 months LT)
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change From Baseline in Hemoglobin A1 (A1C) at Week 24
大体时间:Baseline, Week 24
|
Mean change from baseline in A1C at Week 24, adjusted for baseline value.
|
Baseline, Week 24
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change From Baseline in A1C at Week 24 - Saxagliptin 5 mg QPM
大体时间:Baseline, Week 24
|
Mean change from baseline in A1C at Week 24, adjusted for baseline value.
|
Baseline, Week 24
|
|
第 24 周空腹血糖 (FPG) 相对于基线的变化
大体时间:基线,第 24 周
|
第 24 周 FPG 相对于基线的平均变化,针对基线值进行了调整。
|
基线,第 24 周
|
|
Percentage of Participants Achieving A1C < 7% at Week 24
大体时间:Week 24
|
Percentage of participants achieving A1C < 7%, the American Diabetes Association's defined goal for glycemia, at each dose of saxagliptin versus placebo at Week 24.
|
Week 24
|
|
Changes From Baseline in Postprandial Glucose (PPG) Area Under the Curve (AUC) Response to an Oral Glucose Tolerance Test (OGTT) at Week 24
大体时间:Baseline, Week 24
|
Mean change from baseline for 0 to 180 minutes PPG AUC at Week 24, adjusted for baseline value.
|
Baseline, Week 24
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
赞助
出版物和有用的链接
负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。
一般刊物
- Perl S, Cook W, Wei C, Iqbal N, Hirshberg B. Saxagliptin Efficacy and Safety in Patients With Type 2 Diabetes and Moderate Renal Impairment. Diabetes Ther. 2016 Sep;7(3):527-35. doi: 10.1007/s13300-016-0184-9. Epub 2016 Jul 11.
- Bonora E, Bryzinski B, Hirshberg B, Cook W. A post hoc analysis of saxagliptin efficacy and safety in patients with type 2 diabetes stratified by UKPDS 10-year cardiovascular risk score. Nutr Metab Cardiovasc Dis. 2016 May;26(5):374-9. doi: 10.1016/j.numecd.2015.11.004. Epub 2015 Dec 1.
- Frederich R, McNeill R, Berglind N, Fleming D, Chen R. The efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-naive patients with type 2 diabetes mellitus: a randomized controlled trial. Diabetol Metab Syndr. 2012 Jul 24;4(1):36. doi: 10.1186/1758-5996-4-36.
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始
2006年6月1日
初级完成 (实际的)
2007年11月1日
研究完成 (实际的)
2008年11月1日
研究注册日期
首次提交
2006年4月18日
首先提交符合 QC 标准的
2006年4月19日
首次发布 (估计)
2006年4月20日
研究记录更新
最后更新发布 (估计)
2015年4月29日
上次提交的符合 QC 标准的更新
2015年4月8日
最后验证
2015年3月1日
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.